News | July 24, 2025
Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Subscribe To Our Newsletter & Stay Updated
